GLPwatch
Mounjaro for Bipolar disorder
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for bipolar disorder, and any use for this condition is off-label or investigational. A pharmacovigilance analysis linked tirzepatide to psychiatric adverse events, but this does not establish a treatment effect for bipolar disorder.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Bipolar disorder |
| Approval status | Investigational / off-label |
| Research papers | 1 |
Mounjaro is not FDA-approved for bipolar disorder; the research below reflects investigational or off-label study only.